Key result
Cancer survivors face an increased risk of cardiovascular disease and death, partly due to anticancer therapies such as anthracyclines, trastuzumab, and chest radiation.
Why the study?
Should cancer history be included in cardiovascular risk prediction tools?
Should cancer history be included in cardiovascular risk prediction tools?
Answers are grounded in this paper and cite their sources.
Highlights the growing population of cancer survivors and their increased cardiovascular risk, advocating for the potential inclusion of cancer history in cardiovascular risk prediction tools.
The number of cancer survivors worldwide has grown substantially to more than 16 million individuals in the USA. More than 65% of adults diagnosed with cancer live for at least 5 years after diagnosis, and a growing number of individuals live longer than that.1 Although more individuals are cured from cancer or are living longer with cancer, evidence has been emerging that cancer survivors are at an increased risk of and death from cardiovascular disease.2 Some anticancer therapies, such as anthracyclines, trastuzumab, and chest radiation, have been known for decades to increase cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Blaes et al. (2019) conducted an editorial in Cancer and cardiovascular disease. Cancer and anticancer therapies was evaluated. Cancer survivors face an increased risk of cardiovascular disease and death, partly due to anticancer therapies such as anthracyclines, trastuzumab, and chest radiation.
Synapse has enriched 10 related papers. Consider them for comparative context: